Related Experiment Video
Updated: Dec 1, 2025
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Novel 2,7-Diazaspiro[4,4]nonane Derivatives to Inhibit Mouse and Human Osteoclast Activities and Prevent Bone Loss in
Lucile Mounier1, Anne Morel1, Yann Ferrandez2
1Centre de Recherche en Biologie Cellulaire de Montpellier, Univ Montpellier, CNRS, Montpellier, France, Université de Montpellier, CNRS, 34000 Montpellier, France.
Abstract:
Osteoporosis is currently treated with drugs targeting the differentiation or viability osteoclasts, the cells responsible for physiological and pathological bone resorption. Nevertheless, osteoporosis drugs that target only osteoclast activity are expected to preserve bone formation by osteoblasts in contrast to current treatments. We report here the design, synthesis, and biological characterization of a series of novel N-arylsufonamides featuring a diazaspiro[4,4]nonane nucleus to target the guanine nucleotide exchange activity of DOCK5, which is essential for bone resorption by osteoclasts. These compounds can inhibit both mouse and human osteoclast activity. In particular, 4-chlorobenzyl-4-hydroxy-2-phenyl-1-thia-2,7-diazaspiro[4,4]nonane 1,1-dioxide (compound E197) prevented pathological bone loss in mice. Most interestingly, treatment with E197 did not affect osteoclast and osteoblast numbers and hence did not impair bone formation. E197 could represent a lead molecule to develop new antiosteoporotic drugs targeting the mechanism of osteoclast adhesion onto the bone.
Insights
Novel N-arylsulfonamides targeting DOCK5 inhibit osteoclast activity, offering a new therapeutic strategy for osteoporosis. Compound E197 prevents bone loss without affecting bone formation, preserving osteoblast and osteoclast numbers.
Area of Science:
- Biochemistry
- Pharmacology
- Bone Biology
Background:
- Current osteoporosis treatments target osteoclast differentiation or viability, potentially impacting bone formation.
- There is a need for osteoporosis therapies that selectively inhibit osteoclast activity while preserving bone formation.
- Osteoclast-mediated bone resorption is a key process in osteoporosis pathogenesis.
Purpose of the Study:
- To design, synthesize, and biologically characterize novel N-arylsulfonamides targeting DOCK5's guanine nucleotide exchange activity.
- To evaluate the efficacy of these compounds in inhibiting osteoclast activity and preventing bone loss.
- To assess the impact of the lead compound on osteoclast and osteoblast numbers and bone formation.
Main Methods:
- Synthesis of N-arylsulfonamides with a diazaspiro[4,4]nonane nucleus.
- Biological characterization of compounds for inhibition of mouse and human osteoclast activity.
- In vivo studies using a mouse model of pathological bone loss to evaluate compound E197 efficacy and bone parameters.
Main Results:
- A series of novel N-arylsulfonamides targeting DOCK5 were synthesized and characterized.
- Compounds demonstrated inhibition of both mouse and human osteoclast activity.
- Compound E197 effectively prevented pathological bone loss in mice without altering osteoclast or osteoblast numbers, thus not impairing bone formation.
Conclusions:
- Novel N-arylsulfonamides targeting DOCK5 represent a promising new class of anti-osteoporosis drug candidates.
- Compound E197 is a lead molecule that inhibits osteoclast activity and bone resorption while preserving bone formation.
- Targeting DOCK5 offers a potential therapeutic strategy for osteoporosis by modulating osteoclast adhesion and function.
